Vision-threatening uveitis of unknown origin

Article

What to investigate: aqueous, vitreous or both?

The main advantage of diagnostic vitrectomy is obviously a larger volume of sample which allows a more thorough analysis and multiple investigations in one sample. In addition, vitrectomy may improve visual acuity, but its drawback is its invasiveness, possibility of adverse effects and higher costs.

In contrast, aqueous analysis is a less invasive procedure and may yield results faster. However, an aqueous tap provides a restricted volume of the sample (usually around 100–200 microlitres) and, therefore, allows only a limited number of examinations.

Conversely, outside Europe, diagnostic vitrectomy is frequently being performed as a primary surgical diagnostic procedure, and the acquired material is being assessed by PCR and other various methods including microbial cultures, cytology, immunophenotyping by flow cytometry and other examinations, usually based on clinical manifestations of the patients.

GWC is a more elaborate diagnostic assay than PCR and is, therefore, not universally used. Obviously, the simultaneous analyses of vitreous sample provide the most valuable assessment and prevent the need for multiple diagnostic interventions, but may limit the volume of separate samples. The diagnostic value of vitrectomy varies widely, which is certainly caused by the number of examinations performed with a given sample and by the selection of patients. The selection based on a clinical suspicion of specific diagnosis increases the positive outcome of a diagnostic procedure.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.